Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001193125-25-042458
Filing Date
2025-02-28
Accepted
2025-02-28 16:02:40
Documents
15
Effectiveness Date
2025-02-28

Document Format Files

Seq Description Document Type Size
1 S-8 d935377ds8.htm S-8 36979
2 EX-5.1 d935377dex51.htm EX-5.1 5214
3 EX-23.2 d935377dex232.htm EX-23.2 1578
4 EX-FILING FEES d935377dexfilingfees.htm   iXBRL EX-FILING FEES 36257
  Complete submission text file 0001193125-25-042458.txt   232355

Data Files

Seq Description Document Type Size
17 EXTRACTED XBRL INSTANCE DOCUMENT d935377dexfilingfees_htm.xml XML 14043
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-285414 | Film No.: 25689895
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)